ASKA PHARMACEUTICAL HOLDINGS CO.,LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,260 JPY | +0.09% |
|
+2.40% | +26.68% |
| Sales 2024 * | 63.28B 407M | Sales 2025 * | 64.65B 416M | Capitalization | 64.02B 412M |
|---|---|---|---|---|---|
| Net income 2024 * | 6.47B 41.63M | Net income 2025 * | 4.89B 31.51M | EV / Sales 2024 * | 0.75 x |
| Net cash position 2024 * | 16.35B 105M | Net cash position 2025 * | 20.83B 134M | EV / Sales 2025 * | 0.67 x |
| P/E ratio 2024 * |
9.89
x | P/E ratio 2025 * |
13.1
x | Employees | 747 |
| Yield 2024 * |
1.77% | Yield 2025 * |
2.12% | Free-Float | 0% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.09% | ||
| 1 week | +2.40% | ||
| Current month | +1.85% | ||
| 1 month | +2.26% | ||
| 3 months | +13.68% | ||
| 6 months | +32.16% | ||
| Current year | +26.68% |
1 week
2 215.00
2 314.00
1 month
2 145.002 314.00
Current year
1 787.002 314.00
1 year
1 207.002 314.00
3 years
919.002 314.00
5 years
776.002 314.00
10 years
772.002 314.00
| Managers | Title | Age | Since |
|---|---|---|---|
| President | 71 | 21-03-31 | |
Kiyohiko Tamura
ADM | Chief Administrative Officer | - | - |
Kunihiro Gunji
CMP | Compliance Officer | - | 21-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| President | 71 | 21-03-31 | |
Atsushi Maruo
BRD | Director/Board Member | 65 | 21-03-31 |
| Director/Board Member | 75 | 21-03-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.08% | 15 M€ | +7.34% | ||
| 0.01% | 18 M€ | +16.15% | - | |
| 0.00% | 144,586 M€ | +14.49% | ||
| 0.00% | 66,066 M€ | +14.68% | - | |
| 0.00% | 20,721 M€ | +13.52% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 2,260 | +0.09% | 45,100 |
| 24-04-25 | 2,258 | -0.22% | 52,100 |
| 24-04-24 | 2,263 | +1.07% | 38,400 |
| 24-04-23 | 2,239 | +0.77% | 28,800 |
| 24-04-22 | 2,222 | +0.68% | 22,100 |
Delayed Quote Japan Exchange, April 26, 2024 at 02:00 am EDT
More quotes
ASKA Pharmaceutical Holdings Co Ltd is a Japan-based company mainly engaged in the pharmaceutical business. The Company mainly operates in two business segments. The Pharmaceutical segment is mainly engaged in the manufacture, purchase and sale of pharmaceutical products. The Others segment is involved in the manufacture of veterinary drugs, the provision of clinical testing services, the outsourcing of testing services, the purchase and sale of medical equipment, as well as the sale of health foods.
Sector
Pharmaceuticals
Calendar
2024-05-09
- Q4 2023 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2,260
JPY
Average target price
2,667
JPY
Spread / Average Target
+17.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +26.68% | 407M | |
| +25.83% | 661B | |
| +27.35% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +14.45% | 231B | |
| +4.54% | 200B | |
| -9.37% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 4886 Stock
